This is an educational resource for primary healthcare professionals. It summarises the current guidelines from Australia and the UK to optimise the NZ management of heavy menstrual bleeding (HMB). Most patients with HMB can be effectively investigated and managed in primary care, utilising non-hormonal and hormonal treatments such as a levonorgestrel-releasing intrauterine device. Healthcare professionals should, however, have increased suspicion of endometrial hyperplasia or cancer in patients with risk factors, especially among Māori and Pacifica women in whom incidence rates are increasing. This publication has been commissioned by Bayer. The production of the content is entirely independent, but has been reviewed by Bayer for technical accuracy prior to publication.
Please login below to download this issue (PDF)